Document:

CONFIDENTIAL TREATMENT REQUESTED. Confidential
portions of this document have been redacted and have been separately filed with the Commission. 

Exhibit 10.6

 

  

EXCLUSIVE LICENSE AGREEMENT

 

THIS EXCLUSIVE LICENSE AGREEMENT
(the “Agreement”) is made and entered into as of the 17th day of March, 2015 (the “Effective Date”)
by and between Mustang Therapeutics, Inc., a Delaware corporation with a principal place of business at 3 Columbus Circle, New
York, NY 10019 (“Licensee”) and City of Hope, a California nonprofit public benefit corporation located at 1500
East Duarte Road. Duarte, California 91010 (“City of Hope” or “COH”). Licensee and
COH are each sometimes referred to herein individually as a “Party” and collectively as the “Parties.”

 

WHEREAS:

 

A.           COH
operates an academic research and medical center that encourages the use of its inventions, discoveries and intellectual property
for the benefit of the public and COH owns or Controls (as defined below) certain Patent Rights (as defined below) useful in the
Field (as defined below);

 

B.           The
inventions covered by the Patent Rights were invented by Dr. Stephen Forman who, as of the Effective Date, is affiliated with COH;

 

C.           The
research was sponsored in part by the National Institute of Health, and as a consequence this license is subject to obligations
to the United States Federal Government under 35 U.S.C. §§ 200-212 and applicable U.S. government regulations;

 

D.           Licensee
is a company dedicated to the commercial development and exploitation in the Field (as defined below) of products and services
that incorporate one or more of the technologies described in the Patent Rights and therefore Licensee desires to obtain from COH
a worldwide, exclusive license under the Patent Rights, on the terms and subject to the conditions set forth herein;

 

E.           On
even date herewith, the Parties have entered into the Research Agreement pursuant to Section of this Agreement; and 4.6

 

F.           The
Certificate of Incorporation of Licensee is in the form attached hereto as Exhibit A (the “Charter”)
and provides, among other things, for the rights and preferences of a class of stock, referred to therein as Class A Common Stock,
to be issued to COH or its designee(s) in accordance with the terms of this Agreement.

 

NOW, THEREFORE, in consideration
of the mutual covenants contained herein, and for other good and valuable consideration, the amount and sufficiency of which are
hereby acknowledged, the Parties hereby agree as follows:

 

    	 	1	 

     

      

CONFIDENTIAL 

ARTICLE 1:          DEFINITIONS

 

1.1           “Act”
means the Securities Act of 1933, as amended.

 

1.2           “Affiliate”
of a Party means a Person that, directly or indirectly (through one or more intermediaries) controls, is controlled by, or is under
common control with such Party. For purposes of this Section 1.2, “control” means (i) the direct or indirect ownership
of 50 percent or more of the voting stock or other voting interests or interests in profits, or (ii) the ability to otherwise control
or direct the decisions of board of directors or equivalent governing body thereof.

 

1.3           “Business
Day’’ means any day, other than a Saturday, Sunday or day on which commercial banks located in Los Angeles,
California, are authorized or required by law or regulation to close.

 

1.4           “Change
of Control” means (i) any transaction or series of related transactions following which the holders of Licensee’s
capital stock immediately prior to such transaction or series of related transactions collectively are the owners of less than
50% of the outstanding equity interests of Licensee entitled to (a) vote with respect to the election of directors (or positions
having a similar function) or (h) receive the proceeds upon any sale, liquidation or dissolution of Licensee, (ii) a sale, transfer,
exclusive license or other disposition, in a single transaction or series of related transactions, of all or a material portion
of Licensee’s interest in the Licensed Product or Licensed Service or (iii) a sale, transfer, exclusive license or other
disposition, in a single transaction or series of related transactions, of all or a material portion of Licensee’s right
title, or interest in its assets taken as a whole.

 

1.5           “Class
A Common Stock” means Class A Common Stock, par value $0.0001 per share, of Licensee, with such
rights preferences and privileges as are set forth in the Charter.

 

1.6           “Commercially
Reasonable Efforts” means the exercise of such efforts and commitment of such resources by Licensee, directly
or through one or more Sublicensees, in a diligent manner consistent with organizations in the pharmaceutical industry for a comparable
development or commercialization program at a similar stage of development or commercialization. In the event that Licensee or
a Sublicensee with respect to a given Licensed Product or Licensed Service, has a program or product that competes with the programs
contemplated by this Agreement with respect to such Licensed Product or Licensed Service, then “Commercially Reasonable Efforts”
shall also mean efforts at least comparable to those efforts and resources expended by Licensee or its Sublicensee on the competing
program and/or product or service.

 

1.7           “COH
Shares” means the shares of Class A Common Stock to be issued to COH Stockholders in accordance with Section 4.3
and/or the terms of the Charter upon a Change of Control or Qualified Public Offering.

 

1.8           “COH
Confidential Information” means Confidential Information disclosed or provided by, or on behalf of, COH to Licensee
or its designees.

 

1.9           “Completion”
means, with respect to a particular clinical trial, the earlier of (i) the database lock or freeze related to the completion of
treatment or examination of participants in such clinical trial or (ii) the dosing of the first patient in a clinical trial in
a subsequent phase (e.g., with respect to a Phase 1 Clinical Trial, the Phase 1 Clinical Trial will be deemed completed in the
event a patient is dosed in a Phase 2 Clinical Trial before a database lock in the related Phase 1 Clinical Trial).

 

    	 	2	 

     

      

CONFIDENTIAL

 

1.10         “Common
Stock” means Common Stock, par value $.001 per share, of Licensee.

 

1.11         “Confidential
Information” means: (i) all information and materials (of whatever kind and in whatever form or medium) disclosed
by or on behalf of a Party to the other Party (or its designee) in connection with this Agreement, whether prior to or during the
term of this Agreement and whether provided orally, electronically, visually or in writing; provided that all such information
and materials initially disclosed in writing or electronically shall be clearly marked as “CONFIDENTIAL” and all such
materials and information initially disclosed orally shall be reduced to writing and marked as “CONFIDENTIAL” within
10 days following the date of initial oral disclosure; (ii) all copies of the information and materials described in (i) above;
and (iii) the existence and each of the terms and conditions of this Agreement; provided further that Confidential Information
shall not include information and materials to the extent a Party can demonstrate through its contemporaneous written records that
such information and materials are or have been:

 

(a)          known
to the receiving Party, or in the public domain, at the time of its receipt by a Party, or which thereafter becomes part of the
public domain other than by virtue of a breach of this Agreement or the obligations of confidentiality under this Agreement;

 

(b)          received
without an obligation of confidentiality from a Third Party having the right to disclose without restrictions such information;

 

(c)          independently
developed by the receiving Party without use of or reference to Confidential Information disclosed by the other Party; or

 

(d)          released
from the restrictions set forth in this Agreement by the express prior written consent of the disclosing Party.

 

1.12         “Control(s)”
or “Controlled” means the possession by a Party, as of the Effective Date, of rights sufficient to effect
the grant of rights set forth in this Agreement without violating the terms of any agreement with any Third Party.

 

1.13         “Covers”
or “Covered by,” means with reference to a particular Licensed Product or Licensed Service that the
manufacture, use, sale, offering for sale, or importation of such Licensed Product or performance of such licensed Service would,
but for ownership of, or a license granted under this Agreement to, the relevant Patent Right, infringe a Valid Claim in the country
in which the activity occurs.

 

1.14         “Dispute”
means any controversy, claim or legal proceeding arising out of or relating to this Agreement, or the interpretation, breach, termination,
or invalidity thereof.

 

1.15         “Field”
means the treatment and diagnosis of all human diseases.

 

    	 	3	 

     

      

CONFIDENTIAL

 

1.16         “First
Commercial Sale” means, with respect to a particular Licensed Product or Licensed Service in a given country, the
first arm’s-length commercial sale of such Licensed Product or the first performance of such Licensed Service following
Marketing Approval in such country by or under authority of Licensee or any Sublicensee to a Third Party who is not a Sublicensee.

 

1.17         “GAAP”
means generally accepted accounting principles, consistently applied, as promulgated from time to time by the Financial Accounting
Standards Board.

 

1.18         “License
Year” means each calendar year during the term of this Agreement; except that the first License Year shall commence
on the Effective Date and end on December 31 of the calendar year in which the Effective Date occurs.

 

1.19         “Licensed
Product” means a product (including kits, component sets or components thereof, regardless of concentration or formulation)
that: (i) is Covered by a Valid Claim. (ii) is manufactured by a process or used in a method Covered by a Valid Claim, or (iii)
contains, as an active ingredient, any substance the manufacture, use, offer for sale or sale of which is Covered by a Valid Claim.
By way of clarification, “Licensed Product” shall include a product manufactured in a country in which such manufacture
is Covered by a Valid Claim and thereafter exported to and sold in a country in which no Valid Claim exists.

 

1.20         “Licensed
Service” means any service the performance of which would, but for the license granted herein, infringe a Valid Claim.

 

1.21         “Licensee
Confidential Information” means Confidential Information disclosed or provided by, or on behalf of, Licensee to COH
or its designees.

 

1.22         “Marketing
Approval” means all approvals, licenses, registrations or authorizations of any federal, state or local regulatory
agency, department, bureau or other governmental entity, necessary for the manufacturing, use, storage, import, transport, marketing
and sale of Licensed Products or performance of Licensed Services in a country or regulatory jurisdiction.

 

1.23         “Net
Proceeds” means the net proceeds actually received by Licensee from all sales of shares of capital stock after deduction
of all transaction expenses, finder’s fees, advisory fees, legal fees, sales commissions or similar amounts paid to brokers
or dealers and other costs and expenses incurred by Licensee or its subsidiaries in connection therewith. In the event such net
proceeds are not paid to Licensee in cash, the value of such net proceeds will be the fair market value of the assets constituting
such net proceeds.

 

1.24         “Net
Sales” means the total gross amount invoiced by Licensee, its Affiliates and its Sublicensees (regardless of whether
and when such invoices are actually paid) on the sale of Licensed Products and Licensed Services to Third Parties (including, without
limitation, the provision of any product by Licensee, its Affiliates or any of its Sublicensee that incorporates a Licensed Product
or Licensed Service but for clarity excluding documented sponsored research and/or development activities, valued at the actual
direct cost of such activities on a fully burdened basis (including reasonable margin for overhead)), less the following items,
as determined from the books and records of Licensee, its Affiliates or its Sublicensees:

 

    	 	4	 

     

      

CONFIDENTIAL

 

(a)          insurance,
handling and transportation charges actually invoiced;

 

(b)          amounts
repaid, credited or allowed for rejection, return or recall;

 

(c)          sales
or other excise taxes or other governmental charges levied on or measured by the invoiced amount (including, without limitation,
value added taxes);

 

(d)          brokerage,
customs and import duties or charges; and

 

(e)          normal
and customary trade and quantity discounts (including chargebacks and allowances) and rebates which relate to the Licensed Products
or Licensed Services.

 

Sales of Licensed Products between or among
Licensee, its Affiliates or its Sublicensees shall be excluded from the computation of Net Sales, except in those instances in
which the purchaser is also the end-user of the Licensed Product sold. Further, transfers of reasonable quantities of Licensed
Product by Licensee, any of its Affiliates or of its Sublicensee to a Third Party that is not a Sublicensee for use in the development
of such Licensed Product (and not for resale) and transfers of industry standard quantities of Licensed Product for promotional
purposes shall not be deemed a sale of such Licensed Product that gives rise to Net Sales for purposes of this Section 1.24.

 

1.25         “Patent
Rights” means: (i) Patent Cooperation Treaty (PC 1) application PCT/ US2014/29109; (ii) PCT application PCT/ US2014/28961;
(iii) U.S. Patent Application No. 62/053,068 (iv) patents, patent applications, continuation and divisional applications and foreign
equivalents that claim the same invention(s) and priority date as the foregoing, (v) continuation-in-part applications that repeat
a substantial portion of any of the foregoing applications, (vi) Letters Patent or the equivalent issued on any of the foregoing
applications throughout the world, and (vii) amendments, extensions, renewals, reissues, and re-examinations of any of the foregoing.
Notwithstanding the foregoing, “Patent Rights” shall only include any continuation-in-part application to the extent
that claims in such continuation-in-part application are supported in the specification of the parent application, unless otherwise
mutually agreed to in writing by the parties to this Agreement.

 

1.26         “Person”
means any person or entity, including any individual, trustee, corporation, partnership, trust, unincorporated organization, limited
liability company, business association, firm, joint venture or governmental agency or authority.

 

1.27         “Phase
1 Clinical Trial” means, as to a specific Licensed Product or Licensed Service, a study as described in 21 C.F.R.
§312.21(a) or a comparable clinical study in a country other than the United States.

 

1.28         “Phase
2 Clinical Trial” means, as to a specific Licensed Product or Licensed Service, a study in humans designed with the
principal purpose of determining initial efficacy and dosing of such Licensed Product in patients for the indication(s) being studied
as described in 21 C.F.R. §312.21(b); or a similar clinical study in a country other than the United States.

 

 

    	 	5	 

     

      

CONFIDENTIAL

 

1.29         “Phase
3 Clinical Trial” means, as to a specific Licensed Product or Licensed Service, a lawful study in humans of the efficacy
and safety of such Licensed Product or Licensed Service, which is prospectively designed to demonstrate statistically whether such
Licensed Product is effective and safe for use in a particular indication in a manner sufficient to file an application to obtain
Marketing Approval to market and sell that Licensed Product or Licensed Service in the United States or another country for the
indication being investigated by the study. as described in 21 C.F.R. § 312.21(c); or similar clinical study in a country
other than the United States.

 

1.30         “Qualified
Financing” means the sale of capital stock of Licensee, in one or more transactions, that constitute a bona fide
equity financing at such time as the Net Proceeds to Licensee from third party investors that are not Affiliates of Licensee in
such equity financing(s) are less than or equal to the Qualified Financing Protection Ceiling; provided that if capital stock of
Licensee is sold in a single transaction or series of related transactions for different purchase prices and any of such shares
of capital stock are included for purposes of determining the number of shares of Qualifying Stock to be issued to COH pursuant
to Section 4.3, each share of capital stock that is sold for the lowest purchase price shall be deemed to be have sold first (regardless
of the date on which such shares are actually sold) and the next number of shares of capital stock that are sold for the next highest
purchase price shall be deemed to have sold next, et cetera, until the Net Proceeds from all such sales (applying all transaction
expenses to the first shares issued (except to the extent that such expenses are calculated on a per share basis, such as sales
commission, which shall be applied only to the shares included in such calculation) are equal to the Qualified Financing Protection
Ceiling.

 

1.31         “Qualified
Financing Protection Ceiling” means $*. 

 

1.32         “Qualified
Public Offering” means the first public offering of the Common Stock of the Company to the general public that is
effected pursuant to a registration statement filed with, and declared effective by, the United States Securities and Exchange
Commission under the Act, as amended, hut, for purposes of clarity shall not include an offering effected pursuant to a registration
statement on Form S-8 or any successor form.

 

1.33         “Qualifying
Stock” means the sum of: (i) the shares of Class A Common Stock issued and to be issued to COH in accordance with
Section 4.3, (ii) the number of shares of Common Stock (excluding (x) the shares referenced in the foregoing subclause (i) and
(y) shares issued to employees, directors and consultants in their capacity as such) of Licensee outstanding. and (iii) the maximum
number of shares of Common Stock of Licensee issuable (assuming the satisfaction of any conditions to exercisability, convertibility
or exchangeability) upon the exercise, conversion or exchange of all evidences of indebtedness, shares or other securities directly
or indirectly convertible into or exchangeable for Common Stock of the Licensee, including all rights, options or warrants to subscribe
for, purchase or otherwise acquire shares of Common Stock of the Licensee but excluding options and rights granted to employees,
directors and consultants in their capacity as such).

 

 

 

*Confidential material
redacted and filed separately with the Commission.

 

    	 	6	 

     

      

CONFIDENTIAL

 

1.34         “Research
Agreement” has the meaning set forth in Section 4.6.

 

1.35         “Sublicensee”
means any Affiliate of Licensee or Third Party which enters into an agreement with Licensee involving the grant to such Affiliate
or Third Party of any rights under the license granted to Licensee pursuant to this Agreement.

 

1.36         “Sublicense
Revenues” means all consideration, in whatever form, due from a Sublicensee in return for the grant of a sublicense
of Licensee’s rights hereunder, excluding consideration in the form of: (i) royalties received by Licensee and calculated
wholly as a function of sales of Licensed Products or Licensed Services, (ii) payments or reimbursement for documented sponsored
research and/or development activities, valued at the actual direct cost of such activities on a fully burdened basis (including
reasonable margin for overhead), (iii) payment or reimbursement of reasonable patent expenses actually incurred or paid by Licensee
and not otherwise reimbursed, or payment of patent expenses required to by paid by Licensee hereunder, (iv) payments for the purchase
of equity in Licensee at the fair market value of such equity, and (v) payments recognized as Net Sales under this Agreement for
which a royalty is payable to COH. By way of clarification, the principal amount of any loan or other extension of credit provided
to Licensee or an Affiliate of Licensee in connection with the grant of a sublicense by Licensee that is other than an arm’s-length
credit relationship shall be deemed to constitute “Sublicense Revenues.”

 

1.37         “Territory”
means the entire world.

 

1.38         “Third
Party” means a Person that is neither a Party to this Agreement nor an Affiliate of a Party.

 

1.39         “Valid
Claim” means a claim of a pending patent application or an issued and unexpired patent included in the Patent Rights
in a particular jurisdiction, which claim has not, in such jurisdiction been finally rejected or been declared invalid or cancelled
by the patent office or a court of competent jurisdiction in a decision that is no longer subject to appeal as a matter of right.

 

ARTICLE 2:          DEVELOPMENT
AND COMMERCIALIZATION EFFORTS

 

2.1           Development
and Commercialization Responsibilities. Licensee shall have the sole right and responsibility for, and control over,
all development, manufacturing and commercialization activities (including all regulatory activities) with respect to Licensed
Products and Licensed Services in the Field.

 

2.2           Licensee
Diligence. Licensee shall use Commercially Reasonable Efforts to develop and commercialize Licensed Products and Licensed
Services in the Field, directly or through one or more Sublicensees. Without limiting the foregoing, if Licensee, directly or through
one or Sublicensees, fails to accomplish any one of the “Diligence Milestones” set forth in this Section 2.2
by the date specified (each a “Deadline Date”) corresponding to such Diligence Milestone, COH shall have the
right, on notice to Licensee, to terminate this Agreement.

 

    	 	7	 

     

     

CONFIDENTIAL

 

	“Deadline Date”	 	“Diligence Milestone”

	 	 	 
	 1. *  from the Effective Date	 	
        Licensee to receive not less than $* through
        any combination of: (i) Net Proceeds from the sale of any equity securities (or securities convertible into or exercisable for
        equity securities) and (ii) unrestricted grants or gifts.

         

	2.  * from the Effective Date	 	
        Licensee to initiate first Phase I Clinical
        Trial for the first Licensed Product or Licensed Service (with COH listed as principal institution for the clinical trial.) Licensee
        may extend this Deadline Date for up to * (*) additional * (*) month periods upon payment of $* to COH, for each month* (*) period.

         

	3.  * from the Effective Date	 	
        Licensee to initiate the first Phase II
        Clinical Trial for the first Licensed Product or Licensed Service (with COH listed as principal institution for the clinical trial.)
        Licensee may extend this Deadline Date for up to * (*) additional * (*) month periods upon payment of $* to COH, for each * month
        (*) period. If, however, this Diligence Milestone is not achieved after these * (*) extensions through no fault of Licensee, this
        Diligence Milestone will be additionally extended for as long as the Research Agreement is in effect.

         

 

2.3           Governance.
COH and Licensee shall each designate one individual to serve as the main point of contact for communications related to development
and commercialization of Licensed Products and Licensed Services under this Agreement (each a “Designated Representative”).
The initial Designated Representative of COH shall be George Megaw and the initial Designated Representative of Licensee shall
be Michael S. Weiss. Each Party may replace its Designated Representative at any time upon prior notice to the other Party. Licensee
shall keep COH reasonably informed as to progress in the development and commercialization of Licensed Products and Licensed Services.
Without limiting the foregoing, on or before January 15 and July 15 of each year during the term of this Agreement, Licensee shall
provide to COH a written report setting forth, in reasonable detail, its activities and achievements with respect to the development
and commercialization of Licensed Products and Licensed Services during the preceding six months (the “Semi-Annual Report”).
The Designated Representatives shall meet in person twice each calendar year to present and discuss the current Semi-Annual
Report at such location and date as mutually agreed. Each Party shall be responsible for all expenses incurred by its Designated
Representative in the participation in such annual meetings.

 

 

 

 *Confidential
material redacted and filed separately with the Commission.

 

    	 	8	 

     

     

CONFIDENTIAL

 

ARTICLE 3:          LICENSE
GRANTS

 

3.1           Grant
of Rights. COH hereby grants to Licensee an exclusive royalty-bearing right and license under the Patent Rights to make,
have made, use, offer for sale, sell and import Licensed Products and to perform Licensed Services, in the Field, in the Territory.
The foregoing grant of rights shall be subject to: (i) the retained rights of the U.S. Government in the Patent Rights pursuant
to 35 U.S.C. §§ 200-212 and applicable U.S. government regulations, (ii) the royalty-free right of COH and its Affiliates
to practice the Patent Rights for educational and research uses, (iii) the right of COH and its Affiliates to publicly disclose
research results including, to the extent applicable, as specified in the Research Agreement, and (iv) the right of COH and its
Affiliates to allow other non-profit institutions to use the Patent Rights for the same purposes as (ii) and (iii).

 

3.2           No
Implied Licenses. Licensee acknowledges that the licenses granted in this Agreement are limited to the scope expressly
granted and that, subject to the terms and conditions of this Agreement, all other rights under all Patent Rights and other intellectual
property rights Controlled by COH are expressly reserved to COH.

 

3.3           Sublicensing.
Licensee shall have the right to sublicense its rights hereunder without the consent of COH, effective on notice to COH. The terms
and conditions of each sublicense of Licensee’s rights hereunder shall be consistent with this Agreement. A true and complete
copy of each sublicense of Licensee’s rights hereunder, as well as any amendment thereto, shall be delivered to COH promptly
following the effective date of each such sublicense or amendment.

 

3.4           Effect
of Termination on Sublicenses.

 

(a)          In
the event that this Agreement terminates at any time for any reason, each sublicense validly granted hereunder which is in good
standing as of the effective date of such termination shall continue in effect as a direct license between COH (as licensor) and
Sublicensee (as licensee), provided that: (i) such sublicense, as determined by COH in its reasonable and good faith discretion,
contains or imposes on COH no material obligation or liability additional to those set forth in this Agreement, (ii) the Sublicensee
delivers to COH, within 30 days of the effective date of the termination of this Agreement, written acknowledgement that all payment
and other obligations previously payable to Licensee under such sublicense shall thereafter be payable and due, and be paid directly
to COH, and (iii) such Sublicensee (including its employees and contractors) is not at such time debarred or excluded or otherwise
ineligible for participation in federally funded programs. All other sublicenses in existence as of the effective date of the termination
of this Agreement which fail to satisfy the foregoing conditions shall, upon such termination, terminate.

 

(b)          Further
and in addition to the requirements of Section 3.4(a), above, the conversion of a sublicense into a direct license between COH
(as licensor) and Sublicensee (as licensee) upon termination of this Agreement shall require that either [A] or [B] (but not both),
below, be satisfied:

 

    	 	9	 

     

     

CONFIDENTIAL

 

[A]           On
the effective date of the termination of this Agreement:

 

(i)          the
Sublicensee is not a party to a proceeding in bankruptcy or insolvency filed by or against such Sublicensee, has not made a general
assignment for the benefit of its creditors, and is not in litigation with COH or any Affiliate of COH and

 

(ii)         (1)
the effective royalty rate payable on Sublicensee’s Net Sales of Licensed Products and Licensed Services, (2) the aggregate
of other non-sale/royalty-based consideration due from Sublicensee, and (3) the other material terms and conditions of the sublicense
are materially no less favorable to COH than the corresponding terms (excluding the stock grant due pursuant to Section 4.3, below)
of this Agreement, or

 

[B]           the
terms and conditions of the sublicense had been approved by COH prior to its having been entered into by Licensee and the Sublicensee,
such approval having been considered by COH expeditiously and not conditioned on the payment by Licensee of any additional consideration.

 

3.5           Documentation
of Licensed Services. Licensee and its Sublicensees shall provide Licensed Services only pursuant to one or more written
agreements which set forth, in reasonable detail, all consideration due to Licensee for the provision of such services. Licensee
shall provide a true and complete copy of each such agreement to COH promptly following the effective date of such agreement.

 

ARTICLE 4:          PAYMENTS

 

4.1           Up-Front
Payment. Licensee shall pay to COH a one-time non-refundable  license
fee of $2 million within * days after the Effective Date.

 

4.2           License
Maintenance Fee. On or before the tenth Business Day after the end of each License Year (excluding the first license Year
ending December 3l, 2015), Licensee shall pay to COH a non-refundable license maintenance fee of $*. The license maintenance fee
paid in a given License Year shall be applied as credit against royalties otherwise due to COH pursuant to Section 4.8, below,
during the License Year in which payment was made but may not be carried over and applied as credit against royalties due in subsequent
years.

 

 

*Confidential material
redacted and filed separately with the Commission.

 

    	 	10	 

     

     

CONFIDENTIAL

 

4.3           Stock
Grant.

 

(a)          Concurrently
with the execution of this Agreement, Licensee will issue to COH stock certificates evidencing 1,000,000 validly issued, fully-paid, non-assessable
shares of Class A Common Stock. At the closing of each Qualified Financing that occurs prior to the achievement of the Qualified
Financing Protection Ceiling, Licensee will issue to COH and such reasonable number of designees as COH may specify (provided that
each such designee has: (i) demonstrated to the reasonable satisfaction of Licensee that it is an “accredited investor”
as such term is defined in Regulation D promulgated under the Securities Act of 1933 (the “Act”), (ii) represented
to Licensee that it is acquiring the shares for investment purposes only, and (iii) acknowledged that the shares to be received
are restricted securities under the Act (COH and its designees collectively, the “COH Stockholders”)),
stock certificates evidencing a number of shares of validly issued, fully-paid, non-assessable shares of Class A Common Stock that
is determined such that upon the completion of such issuance, COH and its designees will hold 10% of the total number of shares
of Qualifying Stock, calculated as of immediately after the closing of such Qualified Financing (the “Measurement Date”).
Promptly after the applicable Measurement Date, Licensee will deliver to the COH Stockholders (i) certificates representing the
shares of Class A Common Stock to be issued in accordance with the foregoing, and (ii) a certificate, executed on behalf of Licensee
by an executive officer of Licensee, showing Licensee’s calculation of the number of shares of Qualifying Stock as of the
Measurement Date, the sales price of each share of capital stock issued in the Qualified Financings, and the gross proceeds and
Net Proceeds of the Qualified Financings and Licensee’s calculation of the shares of Class A Common Stock to be issued to
the COH Stockholders. Such shares of Class A Common Stock will be issued in consideration for the benefits provided to Licensee
under the Agreement and no additional consideration shall be payable for such shares of Class A Common Stock.

 

(c)          COH
and the other COH Stockholders acknowledge and agree that the COH Shares will be restricted securities and will not be registered
with the Securities and Exchange Commission or qualified with any state securities authority and that, accordingly, the COH Shares
may not be distributed, sold or otherwise transferred except pursuant to an effective registration statement under the Act or pursuant
to an available exemption from the registration requirements of the Act.

 

4.4           First
Public Offering Fee. At the closing of the first Qualified Public Offering of stock of Licensee, Licensee shall pay COH
a one-time non-refundable fee of $*. 

 

4.5           Sale
of NewCo Business. Upon any Change in Control of Licensee, Licensee shall pay COH a non-refundable fee of $*.

 

4.6           Research
Funding. Simultaneous with the execution of this Agreement, Licensee shall enter into the separate research agreement
with COH (“Research Agreement”) set forth on Exhibit C. Pursuant to the Research Agreement,
Licensee shall provide COI research funds of $2 million each year for five (5) years, totaling $10 million in research funds (“Research
Funds”). Such Research Funds shall be payable in equal payments of $500,000 on a quarterly basis, with the first
quarterly payment being due and payable thirty (30) days after the Effective Date and thereafter on the next quarterly due
date (January 1, April 1, July 1 or October 1).

 

 

 

*Confidential material
redacted and filed separately with the Commission.

 

    	 	11	 

     

     

CONFIDENTIAL

 

4.7           Milestone
Payments. Within * after the occurrence of each “Milestone
Event” set forth below, Licensee shall pay COH or its designee the amount indicated below for each distinct chimeric
antigen receptor within the scope of the Patent Rights:

 

	Milestone Event	 	Amount Due
	 	 	 
	#1.  Upon the *	 	$*
	#2  Upon the *	 	$*
	#3  Upon *	 	$*
	#4  Upon *	 	$*
	#5  Upon *	 	$*
	#6  Upon *	 	$*

 

in the event that any * is received prior
to the *, then Licensee shall also pay the amount due for occurrence of Milestone Event #3 upon receiving such * (e.g., if * is
received prior to the *, Licensor shall pay COH $*).

 

4.8           Royalties.

 

(a)          Subject
to Subsection (b). below, Licensee shall pay to COH or its designee royalties in an amount equal to (i) * percent of Net Sales
of Licensed Products up to and including $*; (ii) * percent of Net Sales of Licensed Products greater than $* up to and including
$*; and (iii) * percent of Net Sales of Licensed Products that exceed $*. Royalties shall be paid on a Licensed Product-by-Licensed
Product and country-by-country basis until the expiration in each country of the last to expire of the Valid Claims in such country
Covering Licensed Product.

 

(b)          Subject
to Subsection (c), below, Licensee shall pay to COH or its designee royalties in an amount equal to (i) * percent of Net Sales
of Licensed Services up to and including $*; (ii) * percent of Net Sales of Licensed Services greater than $* up to and including
$*; and (iii) * percent of Net Sales of Licensed Services that exceed $*. Royalties shall be paid on a Licensed Service-by-Licensed
Service and country-by-country basis until the expiration in each country of the last to expire of the Valid Claims in such country
Covering Licensed Service.

 

(c)          Beginning in the calendar year of Marketing Approval in any jurisdiction of the first Licensed Product or Licensed
Service by Licensee or Sublicensces and if the total earned royalties paid by Licensee under Sections 4.8(a) and (h) in any such
year cumulatively amounts to less than $1 million for that calendar year (“Minimum Annual Royalty”), Licensee
shall pay to COH on or before February 28 following the last quarter of such year the difference between the $1 million
minimum royalty noted above and the total earned royalty paid by Licensee for such year under Sections 4.8(a) and (b),
provided, however. that for the first year of commercial sales of the first Licensed Product or Licensed Services, the amount
of minimum annual royalty payable shall be pro-rated for the number of months remaining in that calendar year.

 

 

 

*Confidential material
redacted and filed separately with the Commission.

 

    	 	12	 

     

      

CONFIDENTIAL

 

4.9           Royalty
Offsets. If, in Licensee’s reasonable business judgment it is necessary to pay to a Third Party other than a Sublicensee
consideration (whether in the form of a royalty or otherwise) for the right to make, have made, use, sell, offer for sale or import
a Licensed Product or Licensed Service in a given jurisdiction, and if the aggregate royalty rates of any and all royalties payable
to such Third Party licensors when combined with the royalty rate payable to COH exceeds * percent in the case of Net Sales of
Licensed Products or Licensed Services, then Licensee shall have the right with respect to any period for which royalties are due
(i.e. a calendar quarter or calendar year) to set off * percent of the aggregate royalties otherwise payable with respect to such
period and such jurisdiction to such Third Party licensors against royalties that would otherwise be due to COH hereunder with
respect to such period and jurisdiction; provided. however, that each Third Party licensor agrees to be stacked proportionally;
and provided further, however, that under no circumstances shall the royalty offsets permitted in this Section 4.9 result in the
reduction of the effective adjusted royalty rate and the royalty amount otherwise due to COH in any period for which payment is
due and in any jurisdiction pursuant to Section 4.8, above, by more than * percent (e.g., minimum effective adjusted royalty rate
for Licensed Product or Licensed Services sales up to $* shall be * percent).

 

4.10         Sublicense
Revenues. Licensee shall pay to COH a percentage of all Sublicense Revenues within * after payment is received from the
relevant Sublicensee, determined as follows:

 

(a)          *
percent of Sublicense Revenues if the Sublicense is granted prior to the *,

 

(b)          *
percent of all Sublicense Revenues if the Sublicense is granted prior to the *,

 

(c)          *
percent of all Sublicense Revenues if the Sublicense is granted prior to the *, and

 

(d)          *
percent of all Sublicense Revenues if the Sublicense is granted after *.

 

If Sublicense Revenues are not in cash
or cash equivalents, the percentage share payable to COH pursuant to this Section 4.10 shall be due, in COH’s sole discretion,
either in kind or in its cash equivalent.

 

4.11         Timing
of Royalty Payments. Royalty payments due under Section 4.8, above, shall be paid annually within *
 following the end of each License Year until the first License Year in which aggregate Net Sales reach $*. Thereafter,
all royalty payments due under Section 4.8 shall be paid in quarterly installments, within * following the end of each calendar
quarter.

 

 

 

*Confidential material
redacted and filed separately with the Commission.

 

    	 	13	 

     

     

CONFIDENTIAL

 

4.12         No
Deductions from Payments. Licensee is solely responsible for payment of any fee, royalty or other payment due to any Third
Party not a Sublicensee in connection with the research, development, manufacture, distribution, use, sale, import or export of
a Licensed Product or Licensed Service and, except as set forth in Section 4.9, above, Licensee shall not have the right to set
off any amounts paid to such a Third Party, including fee, royalty or other payment, against any amount payable to COH hereunder.

 

4.13         Single
Royalty. Only a single royalty payment shall be due and payable on Net Sales of a Licensed Product or performance
of a Licensed Service, regardless if such Licensed Product or Licensed Service is Covered by more than one Valid Claim.

 

ARTICLE 5:          REPORTS,
AUDITS AND FINANCIAL TERMS

 

5.1           Royalty
Reports. Within * after the end of each calendar quarter in which a
royalty payment under Article 4 is required to be made. Licensee shall send to COH a report of Net Sales of the Licensed Products
and Licensed Services for which a royalty is due, which report sets forth for such calendar quarter the following information,
on a Licensed Product-by-Licensed Product, Licensed Service-by-Licensed Service and country-by-country basis: (i) total Net Sales,
(ii) total gross sales of Licensed Products and Licensed Services, (iii) the quantity of each Licensed Products sold and Licensed
Services performed, (iv) the exchange rate used to convert Net Sales from the currency in which they are earned to United States
dollars; and (v) the total royalty payments due.

 

5.2           Additional
Financial Terms.

 

5.2.1           Currency.
All payments to be made under this Agreement shall be made in United States dollars, unless expressly specified to the contrary
herein. Net Sales outside of the United States shall be first determined in the currency in which they are earned and shall then
be converted into an amount in United States dollars. All currency conversions shall use the conversion rate reported by Reuters,
Ltd. on the last Business Day of the calendar quarter for which such payment is being determined.

 

5.2.2           Payment
Method. Amounts due under this Agreement shall be paid in immediately available funds, by means of wire transfer to an
account identified by COH.

 

5.2.3           Withholding
of Taxes. Licensee may withhold from payments due to COH amounts for payment of any withholding tax that is required by
law to be paid to any taxing authority with respect to such payments. Licensee shall provide to COH all relevant documents and
correspondence, and shall also provide to COH any other cooperation or assistance on a reasonable basis as may be necessary to
enable COH to claim exemption from such withholding taxes and to receive a full refund of such withholding tax or claim a foreign
tax credit. Licensee shall give COH proper evidence from time to time as to the payment of such tax. The Parties shall cooperate
with each other in seeking deductions under federal and state tax laws and any double taxation or other similar treaty or agreement
from time to time in force.

 

 

 

*Confidential material
redacted and filed separately with the Commission.

 

    	 	14	 

     

     

CONFIDENTIAL

 

5.2.4           Late
Payments. Any amounts not paid on or before the date due under this Agreement are subject to interest from the date due
through and including the date upon which payment is received. Interest is calculated, over the period between the date due and
the date paid, at a rate equal to *  percentage point (* %) over the “bank
prime loan” rate, as such rate is published in the U.S. Federal Reserve Bulletin H.15 or successor thereto on the last Business
Day of the applicable calendar quarter prior to the date on which such payment is due.

 

5.2.5           Blocked
Currency. If, at any time, legal restrictions prevent the prompt remittance of part or all royalties with respect to any
country where a Licensed Product is sold or Licensed Service provided, payment shall be made through such lawful means or methods
as Licensee may determine. When in any country, the law or regulations prohibit both the transmittal and deposit of royalties or
other payments, Licensee shall continue to report all such amounts, but may suspend payment for as long as such prohibition is
in effect. As soon as such prohibition ceases to be in effect, all amounts that would have been obligated to be transmitted or
deposited but for the prohibition, together with accrued interested thereon, shall promptly be transmitted to COH.

 

5.3           Accounts
and Audit.

 

5.3.1           Records.
Licensee shall keep, and shall require that each Sublicensee keep, full, true and accurate books of account containing the
particulars of its Net Sales and the calculation of royalties. Licensee and its Sublicensees shall each keep such books of account
and the supporting data and other records at its principal place of business. Such books and records must be maintained available
for examination in accordance with this Section 5.3.1 for * after the end of the calendar year to which they pertain, and otherwise
as reasonably required to comply with GAAP.

 

5.3.2           Appointment
of Auditor. COH may appoint an internationally recognized independent accounting firm reasonably acceptable to Licensee
to inspect the relevant books of account of Licensee and its Sublicensees to verify any reports or statements provided, or amounts
paid or invoiced (as appropriate), by Licensee or its Sublicensees.

 

5.3.3           Procedures
for Audit. COH may exercise its right to have Licensee’s and its Sublicensees’ relevant records examined only
during the * period during which Licensee is required to maintain records, no more than once in any consecutive four calendar quarters.
Licensee and its Sublicensees are required to make records available for inspection only during regular business hours, only at
such place or places where such records are customarily kept, and only upon receipt of at least * advance notice from COH.

 

5.3.4           Audit
Report. The independent accountant will be instructed to provide to COH an audit report containing only its conclusions
and methodology regarding the audit, and specifying whether the amounts paid were correct and, if incorrect, the amount of any
underpayment or overpayment.

 

 

 

*Confidential material
redacted and filed separately with the Commission.

 

    	 	15	 

     

     

CONFIDENTIAL

 

 

5.3.5           Underpayment
and Overpayment. After review of the auditor’s report: (i) if there is an uncontested underpayment by Licensee for
all of the periods covered by such auditor’s report, then Licensee shall pay to COH the full amount of that uncontested underpayment,
and (ii) if there is an uncontested overpayment for such periods, then COH shall provide to Licensee a credit against future payments
(such credit equal to the full amount of that overpayment), or, if Licensee is not obligated to make any future payments, then
COH shall pay to licensee the full amount of that overpayment. Contested amounts are subject to dispute resolution under Article
12. If the total amount of any such underpayment (as agreed to by Licensee or as determined under Article 12) exceeds *
percent of the amount previously paid by Licensee for the period subject to audit, then Licensee shall pay the reasonable
costs for the audit. Otherwise, all costs of the audit shall be paid by COH.

 

ARTICLE 6:          LICENSEE
COVENANTS

 

6.1           Licensee
covenants and agrees that:

 

(a)          During
the period commencing on the Effective Date and ending on the third (3rd) anniversary of the Effective Date, both Dr. Lindsay A.
Rosenwald and Michael S. Weiss will hold senior management positions of Licensee; provided, that, in the event of a Change of Control
of Licensee, subsequent to such Change of Control, in the event that either Dr. Lindsay A. Rosenwald or Michael S. Weiss no longer
holds a senior management position of Licensee both individuals must remain materially involved with the oversight and management
of the development of Licensed Products during such period; provided further that in the event of the death of either of Dr. Rosenwald
or Mr. Weiss, the Company will be excused from observing this section with regard to the decedent;

 

(b)          the
Charter and any amendment thereto will provide the holders of Class A Shares with the right to nominate one individual to the board
of directors of Licensee for a period of ten years after the formation of Licensee;

 

(c)          in
conducting activities contemplated under this Agreement, it shall comply in all material respects with all applicable laws and
regulations including, without limitation, those related to the manufacture, use, labeling importation and marketing of Licensed
Products and Licensed Services; and

 

(d)          Licensee
will obtain all authorizations necessary for the issuance of the COH Shares after the date hereof and the Common Stock issuable
to COH upon conversion of the COH Shares issuable pursuant to this Agreement and/or the Charter after the date hereof prior to
the issuance of such COFI Shares and in any event prior to the issuance of any Qualifying Stock or the consummation of a Change
of Control and covenants that all such shares will be validly issued, fully paid and non-assignable and free of restrictions on
transfer, other than restrictions on transfer under state and federal securities laws.

 

 

 

*Confidential material
redacted and filed separately with the Commission.

 

    	 	16	 

     

     

CONFIDENTIAL

 

 

ARTICLE 7:          INTELLECTUAL
PROPERTY; PATENT PROSECUTION, MAINTENANCE AND ENFORCEMENT.

 

7.1           Patent
Prosecution, Maintenance and Enforcement.

 

(a)          COH
shall be responsible for the preparation, filing, prosecution, and maintenance of all Patent Rights, using counsel of its choice.
COH will timely provide Licensee with copies of all relevant documentation relating to such prosecution and Licensee shall keep
such information confidential. In addition, COH shall instruct the patent counsel prosecuting Patent Rights to (i) copy Licensee
on patent prosecution documents that are received from or filed with the United States Patent and Trademark Office and foreign
equivalent, as applicable; (ii) if requested by Licensee, provide Licensee with copies of draft submissions to the USPTO prior
to filing: and (iii) give reasonable consideration to the comments and requests of Licensee or its patent counsel, provided that
(a) COH reserves the sole right to make all final decisions with respect to the preparation, tiling, prosecution and maintenance
of such patent applications and patents; and (b) the patent counsel remains counsel to COH (and shall not jointly represent Licensee
unless requested by Licensee and approved by COH, and an appropriate engagement letter and conflict waiver are in effect). All
patents and patent applications in Patent Rights, to the extent assignable in whole or in part to COH, shall be assigned to COH.

 

(b)          COH
will not unreasonably refuse to amend any patent application in Patent Rights to include claims reasonably requested by Licensee
to protect the products contemplated to be sold by Licensee under this Agreement. If Licensee informs COH of other countries or
jurisdictions in which it wishes to obtain patent protection with respect to the Patent Rights, COH shall prepare, file, prosecute
and maintain patent applications in such counties and any patents resulting therefrom (and, for the avoidance of doubt, such patent
applications and patents shall be deemed included in the Patent Rights). On a country-by-country and patent-by-patent basis, Licensee
may elect to surrender any patent or patent application in Patent Rights in any country upon *
 (*) * advance written notice to COH. Such notice shall relieve Licensee from the obligation to pay for future patent
costs but shall not relieve Licensee from responsibility to pay patent costs incurred prior to the expiration of the * (*) * notice
period. Such U.S. or foreign patent application or patent shall thereupon cease to be a Patent Right hereunder, Licensee shall
have no further rights therein and COH shall be free to license its rights to that particular U.S. or foreign patent application
or patent to any other party on any terms.

 

(c)          Each
Party shall promptly provide written notice to the other in the event it becomes aware of any actual or probable infringement of
any of the Patent Rights in or relevant to the Field or of any Third Party claim regarding the enforceability or validity of any
Patent Rights (“Infringement Notice”). Licensee shall, in cooperation with COH, use reasonable efforts to terminate
infringement without litigation.

 

 

 

*Confidential material
redacted and filed separately with the Commission.

 

    	 	17	 

     

     

CONFIDENTIAL

 

(d)          If
infringing activity has not been abated within * (*) days following the date the Infringement Notice takes effect, then Licensee
may, following consultation with COH, in its sole discretion and at its sole expense, take action against any alleged infringer
or in defense of such any claim, provided, that Licensee has exclusive rights under this Agreement. Any recovery obtained
by Licensee as the result of legal proceedings initiated and paid for by Licensee pursuant to this subsection (d), after deduction
of Licensee’s reasonable out-of-pocket expenses incurred in securing such recovery, shall be deemed to be Net Sales of Licensed
Products and/or Licensed Services in the calendar quarter in which such recovery was received and royalties shall be due and payable
thereon accordingly.

 

(e)          If
COH is involuntarily joined in a suit initiated by Licensee, then the Licensee will pay any costs incurred by COH arising out of
such suit, including but not limited to, reasonable legal fees of counsel that COH selects and retains to represent it in the suit.

 

(f)          In
the event that Licensee declines either to cause such infringement to cease (e.g., by settlement or injunction) or to initiate
and thereafter diligently maintain legal proceedings against the infringer other than as part of a mutually agreed upon bona fide
strategy, developed with the guidance of outside patent counsel, to preserve the Patent Rights, COH may, in its sole discretion
and at its sole expense, take action against such alleged infringer or in defense of any such Third Party claim. Any recovery obtained
by COH as the result of any such legal proceedings shall be for the benefit of COH only.

 

7.2           Trademarks.
Licensee shall be responsible for the selection, registration, maintenance, and defense of all trademarks for use in connection
with the sale or marketing of Licensed Products and Licensed Services in the Field in the Territory (the “Marks”),
as well as all expenses associated therewith. All uses of the Marks by Licensee or a Sublicensee shall comply in all material respects
with all applicable laws and regulations (including those laws and regulations particularly applying to the proper use and designation
of trademarks in the applicable countries). Licensee shall not, without COH’s prior written consent, use any trademarks or
house marks of COH (including the COH corporate name), or marks confusingly similar thereto, in connection with Licensee commercialization
of Licensed Products or Licensed Services under this Agreement in any promotional materials or applications or in any manner implying
an endorsement by COH of Licensee or the Licensed Products or Licensed Services. Licensee shall own all Marks.

 

7.3           Challenge
to the Patent Rights by Licensee.

 

(a)          COH
may terminate this Agreement and, notwithstanding Section 3.3, above, all Sublicenscs issued hereunder, upon written notice to
Licensee in the event that Licensee or any of its Affiliates or Sublicensees directly or indirectly asserts a Patent Challenge.
“Patent Challenge” means any challenge in a legal or administrative proceeding to the patentability,
validity or enforceability of any of the Patent Rights (or any claim thereof), including by: (a) filing or pursuing a declaratory
judgment action in which any of the Patent Rights is alleged to be invalid or unenforceable; (h) citing prior art against any of
the Patent Rights, filing a request for or pursuing a re-examination of any of the Patent Rights (other than with COH’s written
agreement), or becoming a party to or pursuing an interference; or (c) Mina or pursuing any re-examination, opposition. cancellation,
nullity or other like proceedings against any of the Patent Rights; but excluding any challenge raised as a defense against a claim,
action or proceeding asserted by COH against Licensee, its Affiliates or Sublicensees. In lieu of exercising its rights to terminate
tinder this Section 7.3(a) COH may elect upon written notice to increase the payments due under all of Section 4 by *
percent (*%), which election will be effective retroactively to the date of the commencement of the Patent Challenge.
Licensee acknowledges and agrees that this Section 7.3(a) is reasonable, valid and necessary for the adequate protection of COH’s
interest in and to the Patent Rights, and that would not have granted to Licensee the licenses under those Patent Rights, without
this Section.

 

 

*Confidential material
redacted and filed separately with the Commission.

 

    	 	18	 

     

     

CONFIDENTIAL

 

(b)          Payment
of COH Patent Expenses. The Parties acknowledge that, prior to the Effective Date, COH provided to Licensee documentation
of historic expenses incurred by COH with respect to the drafting, prosecution and maintenance of the Patent Rights. In consideration
of such historic expenditures by COH, Licensee shall reimburse COH for such expenses within * of the Effective Date.

 

(c)          After
the Effective Date. COH shall provide to Licensee an annual invoice and reasonably detailed documentation with respect to COH’s
out-of-pocket expenses incurred with respect to such prosecution and maintenance for the previous year. Licensee shall reimburse
COH for * percent of such expenses within * after receipt of such invoice and documentation.

 

7.4           Marking.
Licensee and its Sublicensees shall mark all Licensed Products and all materials related to Licensed Services in such a matter
as to conform with the patent laws of the country to which such Licensed Products are shipped or in which such products are sold
and such Licensed Services performed.

 

ARTICLE 8:          TERM
AND TERMINATION

 

8.1           Term
and Expiration of Term. The term of this Agreement (the “Term”) shall commence on the Effective Date and, notwithstanding
any other provision of this Agreement, unless sooner terminated by mutual agreement or pursuant to any other provision of this
Agreement, this Agreement shall expire on a country-by-country basis and on a Patent Right-by-Patent Right basis on the later to
occur of: (a) the expiration of the last to expire of any of the Patent Rights in such country (or if no patent issues, until the
last patent application in Patent Rights is abandoned), and (b) the date on which the last of the remaining obligations under this
Agreement between the Parties with respect to the payment of milestones or royalties with respect to Licensed Products and Licensed
Services have been satisfied (such expiry of the Term hereinafter referred to as “Expiration”).

 

8.2           Termination.

 

8.2.1           Material
Breach. Either Party may terminate this Agreement prior to its Expiration for any material breach by the other Party,
provided, that, the Party seeking to terminate shall have first given the breaching Party notice of such material breach
with reasonable particulars of the material breach, and the Party receiving the notice of the material breach shall have failed
to cure that material breach within * after the date of receipt of’ such notice.

 

 

 

*Confidential material
redacted and filed separately with the Commission.

 

    	 	19	 

     

     

CONFIDENTIAL

 

8.2.2           Bankruptcy.
COH shall have the right to terminate this Agreement prior to its Expiration upon notice to Licensee, in the event that:
(i) Licensee seeks protection of any bankruptcy or insolvency law other than with the prior consent of City of Hope, or (ii) a
proceeding in bankruptcy or insolvency is filed by or against Licensee and not withdrawn, removed or vacated within *
of such filing, or there is adjudication by a court of competent jurisdiction that Licensee is bankrupt or insolvent.

 

8.2.3           Termination
at Will by Licensee. Licensee shall have the right to terminate this Agreement prior to its Expiration upon notice to COH
without cause, effective no fewer than * following the date of such notice.

 

8.3           Effect
of Termination.

 

8.3.1           Upon
any termination of this Agreement pursuant to Section 8.2 (but for clarity, not in the ease of its Expiration), all rights and
licenses granted to Licensee under Article 4. if any, shall immediately terminate on and as of the effective date of termination
as provided in Section 8.2. except that Licensee shall have the right to continue to sell Licensed Products manufactured prior
to the effective date of such termination until the sooner of: (i) * after the effective date of termination, or (ii) the exhaustion
of Licensee’s inventory of Licensed Products.

 

8.3.2           Upon
termination of this Agreement pursuant to Section 8.2 (but for clarity, not in the case of its Expiration):

 

(a)          Each
Party shall promptly return to the other Party all relevant records and materials in its possession or control containing or comprising
the other Party’s Confidential Information and to which the Party does not retain rights hereunder.

 

(b)          Licensee
shall discontinue making any representation regarding its status as a licensee of COH for Licensed Products and Licensed Services.
Subject to Section 8.3.1, above, Licensee shall cease conducting any activities with respect to the marketing, promotion, sale
or distribution of Licensed Products and Licensed Services.

 

8.3.3           Termination
of this Agreement through any means and for any reason pursuant to Section 8.2 (but for clarity, not in the case of its Expiration),
shall not relieve the Parties of any obligation accruing prior thereto, including the payment of all sums due and payable, and
shall be without prejudice to the rights and remedies of either Party with respect to any antecedent breach of any of the provisions
of this Agreement.

 

8.4           Survival.
Sections 4.11, 5.1, 5.2, 5.3, 7.4, 8.3, 8.4, Article 10, Article 11. Article 12, Sections 14.2, 14.4, 14.7, and 14.10 shall survive
termination of this Agreement for any reason pursuant to Section 8.2 and Expiration pursuant to Section 8.1.

 

 

 

*Confidential material redacted and filed
separately with the Commission.

 

    	 	20	 

     

     

CONFIDENTIAL

 

ARTICLE 9:          REPRESENTATIONS
AND WARRANTIES

 

9.1           Mutual
Representations and Warranties. COH and Licensee each represents and warrants as follows:

 

9.1.1           It
has the right and authority to enter into this Agreement and all action required to be taken on its behalf; its officers, directors,
partners and stockholders necessary for the authorization, execution, and delivery of this Agreement and, the performance of all
of its obligations hereunder, and this Agreement, when executed and delivered, will constitute valid and legally binding obligations
of such Party, enforceable in accordance with its terms, subject to: (i) laws limiting the availability of specific performance,
injunctive relief, and other equitable remedies; and (ii) bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance
or other similar laws now or hereafter in effect generally relating to or affecting creditors’ rights generally;

 

9.1.2           Entry
into this Agreement will not constitute a breach of any other agreement to which it is party;

 

9.1.3           It
has read this Agreement, with assistance from its counsel of choice. It understands all of this Agreement’s terms. It has
been given a reasonable amount of time to consider the contents of this Agreement before each Party executed it. It agrees that
it is executing this Agreement voluntarily with full knowledge of this Agreement’s legal significance; and

 

9.1.4           It
has made such investigation of all matters pertaining to this Agreement that it deems necessary, and does not rely on any statement,
promise, or representation, whether oral or written, with respect to such matters other than those expressly set forth herein.
It agrees that it is not relying in any manner on any statement, promise, representation or understanding, whether oral, written
or implied, made by any Party, not specifically set forth in this Agreement. It acknowledges that, after execution of this Agreement,
it may discover facts different from or in addition to those which it now knows or believes to be true. Nevertheless, it agrees
that this Agreement shall be and remain in full force and effect in all respects, notwithstanding such different or additional
facts.

 

9.2           Representations
and Warranties of COH. COH represents and warrants that, to the actual knowledge of the Investigator (as defined
in the Research Agreement) and the Director of its Office of Technology Transfer without independent inquiry, COH has the full
power and authority to grant the rights, licenses and privileges granted herein.

 

9.3           Representations
and Warranties of Licensee. Licensee represents and warrants as follows:

 

9.3.1           all
authorizations necessary for the issuance of the COH Shares on the date hereof and the Common Stock issuable to COH upon conversion
of the COH Shares issuable to COH pursuant to this Agreement on the date hereof, have been obtained;

 

    	 	21	 

     

     

CONFIDENTIAL

 

9.3.2           no
consent, approval, order, or authorization of, or registration, qualification, designation, declaration, or filing with, any federal,
state, or local governmental authority on the part of Licensee is required in connection with the offer, sale, or issuance of the
COH Shares (and the Common Stock issuable upon conversion of the COH Shares) or the consummation of any other transaction contemplated
hereby, except for the following: (i) the filing of the Charter, which has been filed by Licensee and accepted by the Secretary
of State of the State of Delaware prior to the date of this Agreement in the form attached hereto as Exhibit A; (ii) the
filing of a notice of exemption pursuant to Section 25102(f) of the California Corporate Securities Law of 1968, as amended, which
shall be filed by Licensee promptly following the date hereof and promptly following any Measurement Date; and (iii) the compliance
with other applicable state securities laws, which compliance will have occurred within the appropriate time periods therefor.
The offer, sale, and issuance of the COH Shares in conformity with the terms of this Agreement are exempt from the registration
requirements of Section 5 of the Act, and from the qualification requirements of Section 25110 of the California Securities Law,
and Licensee, nor any authorized agent acting on its behalf will take any action hereafter that prevent the loss of such exemptions;

 

9.3.3           The
sale of the COH Shares is not, and the subsequent conversion of the COH Shares into Common Stock will not be, subject to any preemptive
rights or rights of first refusal that have not been properly waived or complied with;

 

9.3.4           The
COH Shares, when issued, sold and delivered in accordance with the terms of this Agreement for the consideration expressed herein,
will be duly and validly issued, fully paid and nonassessable and free of restrictions on transfer, other than restrictions on
transfer under applicable state and federal securities laws. The common stock issuable upon conversion of the COH Shares has been
duly and validly reserved for issuance and, upon issuance in accordance with the terms of the Charter, will be duly and validly
issued, fully paid and nonassessable and will be free of restrictions on transfer other than restrictions on transfer under applicable
state and federal securities laws;

 

9.3.5           The authorized capital stock of Licensee consists of 50,000,000
shares of Common Stock, 10,000,000 of which will be issued and outstanding on the date hereof (taking into account the issuance
of the COH Shares of Class A Common Stock on the date hereof, and the issuance of the Class B Common Stock). There are no shares
of preferred stock issued or outstanding as of the date hereof. Licensee has also reserved but have not issued an aggregate of
2,000,000 shares of Common Stock for issuance to employees, directors and consultants pursuant to Licensee’s equity incentive
compensation plans. All issued and outstanding shares will have been duly authorized and validly issued and be fully paid and nonassessable.
Other than the COH Shares and the shares of Common Stock issuable upon conversion thereof, there are no other outstanding rights,
options, warrants, preemptive rights, rights of first refusal, or similar rights for the purchase or acquisition from Licensee
of any securities of Licensee nor any commitments to issue or execute any such rights, options, warrants, preemptive rights or
rights of first refusal. The respective rights, preferences, privileges, and restrictions of the Common Stock, including the Class
A Common Stock and Class B Common Stock, are solely as stated in the Charter. Exhibit B sets forth a true and complete capitalization
table of Licensee; and

 

 

    	 	22	 

     

     

CONFIDENTIAL

 

9.3.6           Licensee
is not in violation or default of any provision of the Charter or its bylaws and will not, on any Measurement Date be in such violation
or default.

 

9.4           Exclusions.
Nothing in this Agreement is or shall be construed as:

 

9.4.1           A
warranty or representation by COH as to the validity or scope of any claim or patent or patent application within the Patent Rights;

 

9.4.2           A
warranty or representation by COH that anything made, used, sold, or otherwise disposed of under any license granted in this Agreement
is or will be free from infringement of any patent rights or other intellectual property right of any Third Party;

 

9.4.3           A
grant by COH, whether by implication, estoppel, or otherwise, of any licenses or rights under any patents other than Patent Rights
as defined herein, regardless of whether such patents are dominant or subordinate to Patent Rights;

 

9.4.4           An
obligation on COH to bring or prosecute any suit or action against a third party for infringement of any of the Patent Rights;

 

9.4.5           An
obligation to furnish any know-how not provided in Patent Rights; or

 

9.4.6           A
representation or warranty of the ownership of the Patent Rights other than as set forth in Section 9.2, above.

 

9.5           DISCLAIMER.
NO WARRANTY IS GIVEN WITH RESPECT TO THE PATENT RIGHTS, EXPRESS OR IMPLIED, EITHER IN FACT OR BY OPERATION OF LAW, BY STATUTE OR
OTHERWISE, AND THE PARTIES SPECIFICALLY DISCLAIM ANY EXPRESS OR IMPLIED WARRANTY OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE,
VALIDITY OF THE PATENT RIGHTS OR NON-INFRINGEMENT OF THE INTELLECTUAL PROPERTY OR OTHER RIGHTS OF ANY THIRD PARTY. THE WARRANTIES
SET FORTH IN SECTIONS 9.1 AND 9.2, ABOVE, ARE IN LIEU OF ALL OTHER WARRANTIES, EXPRESS OR IMPLIED, INCLUDING BUT NOT LIMITED TO,
THE IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, VALIDITY, NON-INFRINGEMENT AND ALL SUCH OTHER WARRANTIES
ARE HEREBY EXPRESSLY DISCLAIMED.

 

ARTICLE 10:          INDEMNIFICATION

 

10.1         Indemnification
by Licensee. Licensee shall defend, indemnify and hold harmless COH, its Affiliates, officers, directors, shareholders,
employees and agents (“COH Indemnitees”) from and against any and all Third Party liabilities, claims, suits,
and expenses, including reasonable attorneys’ fees (collectively, “Losses”), arising out of or are in any way
attributable to: (i) the material breach of any representation or warranty made by Licensee under this Agreement, (ii) the research,
development, marketing, approval, manufacture, packaging, labeling, handling, storage, transportation, use, distribution, promotion,
marketing or sale of Licensed Products or Licensed Services by or on behalf of Licensee, any of its Affiliates or a Sublicensee
or any other exercise of rights under this Agreement or pursuant to any sublicense, or (iii) the negligence, willful misconduct
or failure to comply with applicable law by a Licensee Indemnitee or Sublicensee; in each case except to the extent that such Losses
are caused directly by: (a) COH’s material breach of any representation or warranty made by COH under this Agreement, (b)
COH’s material breach of its obligations under this Agreement, and/or (c) the gross negligence or willful misconduct of a
COH Indemnitee.

 

    	 	23	 

     

      

CONFIDENTIAL

 

 

10.2         Indemnification
by COH. COH shall defend, indemnify and hold harmless Licensee and its Affiliates and their respective officers,
directors, shareholders, employees and agents (collectively, the “Licensee Indemnitees”) from and against any and all
Losses caused directly by: (i) the material breach of any representation or warranty made by COH under this Agreement, or (ii)
the gross negligence or willful misconduct of a COH Indemnitee, except to the extent that such Losses arise out of or are in any
way attributable to: (a) the material breach of any representation or warranty made by Licensee under this Agreement, (h) the research,
development, marketing, approval, manufacture, packaging, labeling, handling, storage, transportation, use, distribution, promotion,
marketing or sale of Licensed Products or Licensed Services by or on behalf of Licensee or a Sublicensee, or (c) the negligence,
willful misconduct or failure to comply with applicable law by a Licensee Indemnitee or a Sublicensee.

 

10.3         Procedure.
The indemnities set forth in this Article 10 are subject to the condition that the Party seeking the indemnity shall forthwith
notify. the indemnifying Party on being notified or otherwise made aware of a liability, claim, suit, action or expense
and that the indemnifying Party defend and control any proceedings with the other Party being permitted to participate at its own
expense (unless there shall be a conflict of interest which would prevent representation by joint counsel, in which event the indemnifying
Party shall pay for the other Party’s counsel); provided, that, the indemnifying Party may not settle the liability,
claim, suit, action or expense, or otherwise admit fault of the other Party or consent to any judgment, without the written consent
of the other Party (such consent not to be unreasonably withheld). Notwithstanding the foregoing, no delay in the notification
of the existence of any claim of Loss shall cause a failure to comply with this Section 10.3 as long as such delay shall not have
materially impaired the rights of the indemnifying Party.

 

10.4         Insurance.

 

(a)          Within
* following the Effective Date, Licensee shall procure at its sole expense
and provide to COH evidence of comprehensive or commercial general liability insurance (contractual liability included) with limits
of at least: (i) each occurrence, $*; (ii) products/completed operations aggregate, $*; (iii) personal and advertising injury,
$*; and general aggregate (commercial form only), $*.

 

(b)          The
foregoing policies will provide primary coverage to COH and shall name the COH Indemnitees as additional insureds, and shall remain
in effect during the term of this Agreement and for * following the termination or expiration of the term of this Agreement. The
COH Indemnitees shall be notified in writing by Licensee not less than 30 days prior to any modification, cancellation or non-renewal
of such policy. Licensee’s insurance must include a provision that the coverages will be primary and will not participate
with nor will be excess over any valid and collective insurance or program of self-insurance carried or maintained by the COH Indemnitees.
Such insurance coverage shall be maintained with an insurance company or companies having an A.M. Best’s rating (or its equivalent)
of A-XII or better.

 

 

 

*Confidential material
redacted and filed separately with the Commission.

 

    	 	24	 

     

     

CONFIDENTIAL

 

(c)          Licensee
expressly understands that the coverage limits in Section 10.4(a) do not in any way limit the Licensee’s liability.

 

10.5         LIMITATION
ON DAMAGES. NOTWITHSTANDING ANYTHING CONTAINED IN THIS AGREEMENT TO THE CONTRARY, EXCEPT IN RELATION TO LICENSEE’S INDEMNIFICATION
OBLIGATIONS UNDER SECTION 10.1 AND ANY BREACH BY LICENSEE OF ARTICLE 11: (1) IN NO EVENT SHALL EITHER PARTY BE LIABLE FOR ANY SPECIAL,
PUNITIVE, CONSEQUENTIAL, INDIRECT, OR INCIDENTAL DAMAGES (INCLUDING LOSS OF PROFITS, COSTS OF PROCURING SUBSTITUTE GOODS, LOST
BUSINESS OR ENHANCED DAMAGES FOR INTELLECTUAL PROPERTY INFRINGEMENT) WHETHER BASED UPON BREACH OF WARRANTY, BREACH OF CONTRACT,
NEGLIGENCE, STRICT LIABILITY IN TORT OR ANY OTHER LEGAL THEORY, AND (II) IN NO EVENT SHALL COH BE LIABLE TO LICENSEE FOR AN AGGREGATE
AMOUNT IN EXCESS OF TWO-THIRDS OF THE TOTAL CONSIDERATION PAID TO COH HEREUNDER.

 

ARTICLE 11:          CONFIDENTIALITY

 

11.1         Confidential
Information. During the term of this Agreement and for * thereafter
without regard to the means of termination: (i) COH shall not use, for any purpose other than the purpose contemplated by this
Agreement, or reveal or disclose to any Third Party Licensee Confidential information; and (ii) Licensee shall not use, for any
purpose other than the purpose contemplated by this Agreement, or reveal or disclose COH Confidential Information to any Third
Party. The Parties shall take reasonable measures to assure that no unauthorized use or disclosure is made by others to whom access
to such information is granted.

 

11.2         Exceptions.
Notwithstanding the foregoing, a Party may use and disclose Confidential Information of the other Party as follows:

 

(a)          if
required by applicable law, rule, regulation, government requirement and/or court order, provided, that, the disclosing
Party promptly notifies the other Party of its notice of any such requirement and provides the other Party a reasonable opportunity
to seek a protective order or other appropriate remedy and/or to waive compliance with the provisions of this Agreement;

 

(b)          to
the extent such use and disclosure occurs in the filing or publication of any patent application or patent on inventions;

 

 

 

*Confidential material
redacted and filed separately with the Commission.

 

    	 	25	 

     

     

CONFIDENTIAL

 

(c)          as
necessary or desirable for securing any regulatory approvals, including pricing approvals, for any Licensed Products or Licensed
Services, provided, that, the disclosing Party shall take all reasonable steps to limit disclosure of the Confidential Information
outside such regulatory agency and to otherwise maintain the confidentiality of the Confidential Information;

 

(d)          to
take any lawful action that it deems necessary to protect its interest under, or to enforce compliance with the terms and conditions
of, this Agreement;

 

(e)          to
the extent necessary, to its Affiliates, directors, officers, employees, consultants, vendors and clinicians under written agreements
of confidentiality at least as restrictive as those set forth in this Agreement, who have a need to know such information in connection
with such Party performing its obligations or exercising its rights under this Agreement; and

 

(f)          by
Licensee, to actual and potential investors, licensees, Sublicensees, consultants, vendors and suppliers, and academic and commercial
collaborators, under written agreements of confidentiality at least as restrictive as those set forth in this Agreement.

 

11.3         Certain
Obligations. During the Term and for a period of five years thereafter and subject to the exceptions set forth in Section
11.2, Licensee, with respect to COH Confidential Information, and COH, with respect to Licensee Confidential Information, agree:

 

(a)          to
use such Confidential Information only for the purposes contemplated under this Agreement,

 

(b)          to
treat such Confidential Information as it would its own proprietary information which in no event shall be less than a reasonable
standard of care,

 

(c)          to
take reasonable precautions to prevent the disclosure of such Confidential information to a Third Party without written consent
of the other Party, and

 

(d)          to
only disclose such Confidential Information to those employees, agents and Third Parties who have a need to know such Confidential
Information for the purposes set forth herein and who are subject to obligations of confidentiality no less restrictive than those
set forth herein.

 

11.4        Termination.
Upon termination of this Agreement pursuant to Section 8.2 (but for clarity, not in the case of its Expiration), and upon the request
of the disclosing Party, the receiving Party shall promptly return to the disclosing Party or destroy all copies of Confidential
information received from such Party, and shall return or destroy, and document the destruction of, all summaries, abstracts, extracts,
or other documents which contain any Confidential Information of the other Party in any form, except that each Party shall be permitted
to retain a copy (or copies, as necessary) of such Confidential Information for archival purposes or to enforce or verify compliance
with this Agreement, or as required by any applicable law or regulation.

 

    	 	26	 

     

     

CONFIDENTIAL

 

ARTICLE 12:          DISPUTE
RESOLUTION

 

All Disputes shall
be first referred to a Vice President, Center for Applied Technology Development of COH (the “COH VP”) and the
President of Licensee for resolution, prior to proceeding under the other provisions of this Article 12. A Dispute shall be referred
to such executives upon one Party (the “Initiating Party”) providing the other Party (the “Responding
Party”) with notice that such Dispute exists, together with a written statement describing the Dispute with reasonable
specificity and proposing a resolution to such Dispute that the Initiating Party is willing to accept, if any. Within ten days
after having received such statement and proposed resolution, if any, the Responding Party shall respond with a written statement
that provides additional information, if any, regarding such Dispute, and proposes a resolution to such Dispute that the Responding
Party is willing to accept, if any. In the event that such Dispute is not resolved within *
after the Responding Party’s receipt of the Initiating Party’s notice, either Party may bring and thereafter
maintain suit against the other with respect to such Dispute; provided, however, that the exclusive jurisdiction of any such suit
shall be the state and federal courts located in Los Angeles County, California, and the Parties hereby consent to the exclusive
jurisdiction and venue of such courts.

 

ARTICLE 13:            GOVERNMENTAL
MATTERS

 

13.1        Governmental
Approval or Registration. If this Agreement or any associated transaction is required by the law of any nation to be either
approved or registered with any governmental agency, Licensee shall assume all legal obligations to do so. Licensee shall notify
COH if it becomes aware that this Agreement is subject to a U.S. or foreign government reporting or approval requirement. Licensee
shall make all necessary filings and pay all costs including fees, penalties and all other out-of-pocket costs associated with
such reporting or approval process.

 

13.2        Export
Control Laws. Licensee shall observe all applicable U.S. and foreign laws with respect to the transfer of Licensed Products
and related technical data to foreign countries, including, without limitation, the International Traffic in Arms Regulations and
the Export Administration Regulations.

 

13.3        Preference
for United States Industry. If Licensee sells a Licensed Product in the U.S., Licensee shall manufacture said product substantially
in the U.S.

 

ARTICLE 14:          MISCELLANEOUS

 

14.1         Assignment
and Delegation. Except as expressly provided in this Section 14.1, neither this Agreement nor any right or obligation hereunder
shall be assignable in whole or in part, whether by operation of law, or otherwise by Licensee without the prior written consent
of COH. Notwithstanding the foregoing, Licensee may assign or transfer its rights and obligations under this Agreement to a Person
that succeeds to all or substantially all of that Party’s business or assets, whether by sale, merger, operation of law or
otherwise and provided that such Person agrees, in form and substance reasonably acceptable to COH, to be bound as a direct party
to this Agreement in lieu of or in addition to Licensee and provided further that Licensee has complied with its obligations pursuant
to Section 4.5. This Agreement shall be binding upon and inure to the benefit of and be enforceable by the Parties hereto and their
respective successors and permitted assignees. Any transfer or assignment of this Agreement in violation of this Section 14.1 shall
be null and void.

 

 

 

*Confidential material
redacted and filed separately with the Commission.

 

    	 	27	 

     

     

CONFIDENTIAL

  

14.2         Entire
Agreement. This Agreement and the Research Agreement contains the entire agreement between the Parties relating to the
subject matter hereof, and all prior understandings, representations and warranties between the Parties are superseded by this
Agreement.

 

14.3         Amendments.
Changes and additional provisions to this Agreement shall be binding on the Parties only if agreed upon in writing and signed by
the Parties.

 

14.4         Applicable
Law. This Agreement shall be construed and interpreted in accordance with the laws of the State of California and
all rights and remedies shall be governed by such laws without regard to principles of conflicts of law.

 

14.5         Force
Majeure. If the performance of this Agreement or any obligations hereunder is prevented, restricted or interfered
with by reason of earthquake, fire, flood or other casualty or due to strikes, riot, storms, explosions, acts of God, war, terrorism,
or a similar occurrence or condition beyond the reasonable control of the Parties, the Party so affected shall, upon giving prompt
notice to the other Parties, be excused from such performance during such prevention, restriction or interference, and any failure
or delay resulting therefrom shall not be considered a breach of this Agreement.

 

14.6         Severability.
The Parties do not intend to violate any public policy or statutory common law. However, if any sentence, paragraph, clause or
combination of this Agreement is in violation of any law or is found to be otherwise unenforceable, such sentence, paragraph, clause
or combination of the same shall be deleted and the remainder of this Agreement shall remain binding, provided that such deletion
does not alter the basic purpose and structure of this Agreement.

 

14.7         Notices.
All notices, requests, demands, and other communications relating to this Agreement shall be in writing in the English language
and shall be delivered in person or by mail, international courier or facsimile transmission (with a confirmation copy forwarded
by courier or mail). Notices sent by mail shall be sent by first class mail or the equivalent, registered or certified, postage
prepaid, and shall be deemed to have been given on the date actually received. Notices sent by international courier shall be sent
using a service which provides traceability of packages. Notices shall be sent as follows:

 

	Notices to COH:	with a copy to:
	 	 
	Office of Technology Licensing	Office of General Counsel
	City of Hope	City of Hope
	1500 East Duarte Road	1500 East Duarte Road
	Duarte, CA 91010	Duarte, CA 91010
	Attn: Sr. VP, Center for Applied	Attn: General Counsel
	Technology Development	Fax 626-301-8863
	Fax 626-301-8175	 

 

    	 	28	 

     

     

CONFIDENTIAL

 

	Notices to Licensee:	with a copy to
	 	 
	Mustang Therapeutics, Inc.	Mustang Therapeutics, Inc.
	3 Columbus Circle, 15th Floor	3 Columbus Circle, 15th Floor
	New York, NY 10019	New York, NY 10019
	
        Attn: CEO

         
	 Attn: Corporate Secretary

 

Either Party may change its address for
notices or facsimile number at any time by sending notice to the other Party.

 

14.8         Independent
Contractor. Nothing herein shall create any association, partnership, joint venture, fiduciary duty or the relation
of principal and agent between the Parties hereto, it being understood that each Party is acting as an independent contractor,
and neither Party shall have the authority to bind the other or the other’s representatives in any way.

 

14.9        Waiver.
No delay on the part of either Party hereto in exercising any power or right hereunder shall operate as a waiver thereof, nor
shall any single or partial exercise of any power or right hereunder preclude other or further exercise thereof or the exercise
of any other power or right. No waiver of this Agreement or any provision hereof shall be enforceable against any Party hereto
unless in writing, signed by the Party against whom such waiver is claimed, and shall be limited solely to the one event.

 

14.10        Interpretation.
This Agreement has been prepared jointly and no rule of strict construction shall be applied against either Party. In this
Agreement, the singular shall include the plural and vice versa and the word “including” shall be deemed to be followed
by the phrase “without limitation.” The section headings contained in this Agreement are inserted for convenience only
and shall not affect in any way the meaning or interpretation of this Agreement.

 

14.11         Counterparts.
This Agreement may be executed in counterparts, each of which together shall constitute one and the same Agreement. For purposes
of executing this agreement, a facsimile copy or an emailed PDF of this Agreement, including the signature pages, will be deemed
an original.

 

14.12         Licensee
Certification. Licensee certifies to COH, under penalty of perjury, that Licensee has not been convicted of a criminal
offense related to health care, is not currently debarred, excluded or otherwise ineligible for participation in federally funded
health care programs and has not arranged or contracted (by employment or otherwise) with any employee, contractor, or agent that
it knew or should have known are excluded from participation in any federal health care program, and will not knowingly arrange
or contract with any such individuals or entities during the term of this Agreement. Licensee agrees to notify col4 in writing
immediately of any threatened, proposed or actual conviction relating to health care, of any threatened, proposed or actual debarment
or exclusion from participation in federally funded programs, of COH or any employee, contractor or agent of COH. Any breach of
this Section 14.12 by Licensee shall be grounds for termination of this Agreement by COH in accordance with Section 8.2.1.

 

    	 	29	 

     

     

CONFIDENTIAL

 

14.13         Publicity.
Neither Party may issue a press releases or otherwise disclose the existence or terms of this Agreement without the prior written
consent of the other Party; provided, however, that once the existence or any terms or conditions of this Agreement has
been publicly disclosed in a manner mutually and reasonably agreed-to by the Parties, either Party may republish the facts previously
disclosed without the prior consent of the other Party. COH may, in its sole discretion and without the approval of Licensee, publicly
disclose the existence of this Agreement and the overall potential value of the Agreement to COH, so long as the detailed and specific
terms and conditions of this Agreement are not disclosed. If a third party inquires whether a license is available, COH may disclose
the existence of the Agreement and the extent of its grant in Section 3.1 to such third party, but will not disclose the name of
the Licensee, except where COH is required to release information under either the California Public Records Act or other applicable
law.

 

    	 	30	 

     

     

IN WITNESS WHEREOF,
the Parties have executed this Agreement by their duly authorized representatives.

 

	MUSTANG THERAPEUTICS, INC.	 	CITY OF HOPE

 

	By:	/s/ Michael Weiss	 	By:	/s/ Robert Stone
	 	Michael Weiss	 	 	Robert Stone
	 	President and CEO	 	 	President and CEO

 

    	 	31	 

     

      

 

CONFIDENTIAL TREATMENT REQUESTED. Confidential portions of
this document have been redacted and have been separately filed with the Commission.

Exhibit 10.6

 

EXHIBIT A

 

Form of Charter

 

 

     

     

     

CONFIDENTIAL

 

EXHIBIT B

 

List of Capital Stock Holders

 

*: * 

 

*: *

 

*: *

 

*: *

 

*: *

 

 

 

*Confidential material redacted and filed separately with the
Commission.

 

     

     

     

 

EXHIBIT C

 

Form of Standard Research AgreementExhibit 4.1

 

Unless this certificate is presented by an authorized representative of The Depository Trust Company (55 Water Street, New York, New York) to the issuer or to its agent for registration of transfer, exchange or payment, and any certificate issued is registered in the name of Cede & Co. or such other name as requested by an authorized representative of The Depository Trust Company and any payment is made to Cede & Co., ANY TRANSFER, PLEDGE OR OTHER USE HEREOF FOR VALUE OR OTHERWISE BY OR TO ANY PERSON IS WRONGFUL since the registered owner hereof, Cede & Co., has an interest herein.

 

BEMIS COMPANY, INC.
 3.100% Notes due 2026

 

	
No. 1
    	
$300,000,000
    

 

CUSIP No. 081437 AJ4

 

Bemis Company, Inc., a corporation duly organized and existing under the laws of Missouri (herein called the “Company”, which term includes any successor Person under the Indenture hereinafter referred to), for value received, hereby promises to pay to CEDE & CO, or its registered assigns, the principal sum of $300,000,000 on September 15, 2026, and to pay interest thereon from September 15, 2016 or from the most recent Interest Payment Date to which interest has been paid or duly provided for, semi-annually in arrears on March 15 and September 15 in each year, commencing March 15, 2017, at the rate of 3.100% per annum, until the principal hereof is paid or made available for payment. The interest so payable, and punctually paid or duly provided for, on any Interest Payment Date will, as provided in such Indenture, be paid to the Person in whose name this Note (or one or more Predecessor Securities) is registered at the close of business on the Regular Record Date for such interest, which shall be the March 1 or September 1 (whether or not a Business Day), as the case may be, next preceding such Interest Payment Date. Any such interest not so punctually paid or duly provided for will forthwith cease to be payable to the Holder on such Regular Record Date and may either be paid to the Person in whose name this Note (or one or more Predecessor Securities) is registered at the close of business on a Special Record Date for the payment of such Defaulted Interest to be fixed by the Trustee, notice whereof shall be given to holders of Securities of this series not less than 10 days prior to such Special Record Date, or be paid at any time in any other lawful manner not inconsistent with the requirements of any securities exchange on which the Securities of this series may be listed, and upon such notice as may be required by such exchange, all as more fully provided in said Indenture.

 

Payment of the principal of (and premium, if any) and any such interest on this Note will be made at the office or agency of the Company maintained for that purpose in accordance with the Indenture (which shall initially be the corporate trust office of the Trustee located in St. Paul, Minnesota), in such coin or currency of the United States of America as at the time of payment is legal tender for payment of public and private debts.

 

The Securities of this series are subject to redemption prior to the Stated Maturity as described on the reverse hereof.

 

 

Reference is hereby made to the further provisions of this Note set forth on the reverse hereof, which further provisions shall for all purposes have the same effect as if set forth at this place.

 

Unless the certificate of authentication hereon has been executed by or on behalf of the Trustee referred to on the reverse hereof by manual signature, this Note shall not be entitled to any benefit under the Indenture or be valid or obligatory for any purpose.

 

2

 

IN WITNESS WHEREOF, the Company has caused this instrument to be duly executed under its corporate seal.

 

	
Dated:   September 15, 2016
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
BEMIS   COMPANY, INC.
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
By
    	
 
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
Attest:
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    

 

 

This is one of the Securities of the series designated therein and issued pursuant to the within mentioned Indenture.

 

	
 
    	
U.S.   BANK NATIONAL ASSOCIATION, as Trustee
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
By
    	
 
    
	
 
    	
Name:
    	
 
    
	
 
    	
Title:
    	
 
    

 

 

Bemis Company, Inc.

 

3.100% Notes due 2026

 

This Note is one of a duly authorized issue of securities of the Company (herein called the “Notes”), issued and to be issued in one or more series under an Indenture, dated as of June 15, 1995 (herein called the “Indenture”), between the Company and U.S. Bank National Association (formerly known as First Trust National Association), as Trustee (herein called the “Trustee”, which term includes any successor trustee under the Indenture), to which Indenture and all indentures supplemental thereto reference is hereby made for a statement of the respective rights, limitations of rights, duties and immunities thereunder of the Company, the Trustee and the Holders of the Notes and of the terms upon which the Notes are, and are to be authenticated and delivered. This Note is one of the series designated on the face hereof, limited in aggregate principal amount to $300,000,000.  By the terms of the Indenture, additional Notes of this series and of other separate series, which may vary as to date, amount, Stated Maturity, interest rate or method of calculating the interest rate and in other respects as therein provided, may be issued in an unlimited principal amount.

 

The Company may, at its option, at any time and from time to time, redeem the Notes in whole or in part, on not less than 30 nor more than 60 days’ prior notice mailed to the holders of the Notes (or, as to Notes represented by a global security, sent electronically in accordance with the Depositary’s procedures). At any time prior to the date that is three months prior to the maturity date of the Notes, the Notes will be redeemable at the Company’s option at a redemption price, plus accrued and unpaid interest to the date of redemption, equal to the greater of (1) 100% of the principal amount of the Notes to be redeemed or (2) the sum of the present values of the remaining scheduled payments of principal and interest on the Notes to be redeemed that would be due after the related redemption date but for such redemption as if the Notes matured on such date three months prior to the maturity date (except that, if such redemption date is not an interest payment date, the amount of the next succeeding scheduled interest payment will be reduced by the amount of interest accrued thereon to the redemption date), discounted to the redemption date on a semiannual basis (assuming a 360-day year consisting of twelve 30-day months) at the Treasury Rate plus 25 basis points.  At any time on or after the date that is three months prior to the maturity date of the Notes, the Notes will be redeemable at the Company’s option at a redemption price, plus accrued and unpaid interest to the date of redemption, equal to 100% of the principal amount of the Notes being redeemed.

 

“Treasury Rate” means, with respect to any redemption date, the rate per annum equal to the semi-annual equivalent yield to maturity (computed as of the second Business Day immediately preceding such redemption date) of the Comparable Treasury Issue, assuming a price for the Comparable Treasury Issue (expressed as a percentage of its principal amount) equal to the Comparable Treasury Price for such redemption date.

 

“Comparable Treasury Issue” means the United States Treasury security selected by an Independent Investment Banker that would be utilized, at the time of selection and in accordance with customary financial practice, in pricing new issues of corporate debt securities of comparable maturity to the remaining term of the Notes assuming, for this purpose, that the

 

 

Notes matured three months prior to the maturity date.  “Independent Investment Banker” means one of the Reference Treasury Dealers appointed by the Company.

 

“Comparable Treasury Price” means, with respect to any redemption date, (1) the average of the Reference Treasury Dealer Quotations for such redemption date, after excluding the highest and lowest of such Reference Treasury Dealer Quotations, or (2) if the Independent Investment Banker obtains fewer than four such Reference Treasury Dealer Quotations, the average of all Reference Treasury Dealer Quotations obtained.

 

“Reference Treasury Dealer” means each of BNP Paribas Securities Corp. and J.P. Morgan Securities LLC, or their respective successors, and two other nationally recognized investment banking firms that are primary U.S. government securities dealers located in the United States (“Primary Treasury Dealers”) specified from time to time by the Company, except that if any of the foregoing ceases to be a Primary Treasury Dealer, the Company is required to designate as a substitute another nationally recognized investment banking firm that is a Primary Treasury Dealer.

 

“Reference Treasury Dealer Quotations” means, with respect to each Reference Treasury Dealer and any redemption date, the average, as determined by the Independent Investment Banker, of the bid and asked prices for the Comparable Treasury Issue (expressed in each case as a percentage of its principal amount) quoted in writing to the Independent Investment Banker by such Reference Treasury Dealers as of 3:30 p.m., New York City time, on the third business day preceding such redemption date.

 

In the event of redemption of this Note in part only, a new Note or Notes of this series and of like tenor of an authorized denomination for the unredeemed portion hereof will be issued in the name of the Holder hereof upon the cancellation hereof, and, in the event of transfer or exchange, a new Note or Notes of this series and of like tenor and for a like aggregate principal amount will be issued to the Holder, in the case of exchange, or the designated transferee or transferees, in the case of transfer.

 

Notwithstanding the provisions of Section 1007(b) of the Indenture, the Company and its Restricted Subsidiaries, or any of them, may incur, issue, assume or guarantee Debt secured by Liens without equally and ratably securing the Notes, provided, that at the time of such incurrence, issuance, assumption or guarantee, after giving effect thereto and to the retirement of any Debt which is concurrently being retired, the aggregate amount of all outstanding Debt secured by Liens (excluding Debt secured by liens permitted under Section 1007(a)(1)-(10) of the Indenture) which could not have been incurred, issued, assumed or guaranteed by the Company or a Restricted Subsidiary without equally and ratably securing the Notes except for the provisions of this paragraph, plus the aggregate amount of all Attributable Debt in respect of Sale and Leaseback Transactions existing at such time, does not at such time exceed 10% of Consolidated Net Tangible Assets of the Company.

 

Notwithstanding the provisions of Section 1008(b) of the Indenture, the Company and its Restricted Subsidiaries, or any of them, may enter into a Sale and Leaseback Transaction, provided, that at the time of such transaction, after giving effect thereto, the aggregate amount of all Attributable Debt in respect of Sale and Leaseback Transactions existing at such time which

 

5

 

could not have been entered into except for the provisions of this paragraph, plus the aggregate amount of all outstanding Debt secured by Liens (excluding Debt secured by liens permitted under Section 1007(a)(1)-(10) of the Indenture), does not at such time exceed 10% of Consolidated Net Tangible Assets of the Company.

 

Upon the occurrence of a Change of Control Triggering Event with respect to the Notes, unless the Company has exercised its right to redeem the Notes as described above by giving irrevocable notice to the Trustee in accordance with the Indenture, each holder of the Notes shall have the right to require the Company to purchase all or a portion of such holder’s Notes pursuant to the offer described below (the “Change of Control Offer”), at a purchase price equal to 101% of the principal amount thereof plus accrued and unpaid interest, if any, to the date of purchase (the “Change of Control Payment”), subject to the rights of holders of Notes on the relevant Regular Record Date to receive interest due on the relevant Interest Payment Date.

 

Within 30 days following the date upon which the Change of Control Triggering Event occurred with respect to the Notes, or, at the Company’s option, prior to any Change of Control but after the public announcement of the pending Change of Control, the Company shall send, by first class mail (or, as to Notes represented by a global security, electronically in accordance with the Depositary’s procedures), a notice to each holder of Notes, with a copy to the Trustee, which notice shall govern the terms of the Change of Control Offer. Such notice shall state, among other things, the purchase date, which must be no earlier than 30 days nor later than 60 days from the date such notice is sent, other than as may be required by law (the “Change of Control Payment Date”) or as contemplated by the immediately following sentence. Such notice, if sent prior to the date of consummation of the Change of Control, shall state that the Change of Control Offer is conditioned on the Change of Control being consummated and the Change of Control Triggering Event occurring on or prior to the Change of Control Payment Date.

 

On the Change of Control Payment Date, the Company will, to the extent lawful, (a) accept or cause a third party to accept for payment all Notes or portions of Notes properly tendered pursuant to the Change of Control Offer, (b) deposit or cause a third party to deposit with the Paying Agent an amount equal to the Change of Control Payment in respect of all Notes or portions of Notes properly tendered; and (c) deliver or cause to be delivered to the Trustee the Notes properly accepted together with an Officers’ Certificate stating the aggregate principal amount of Notes or portions of Notes being repurchased and that all conditions precedent to the Change of Control Offer and to the repurchase by the Company of Notes pursuant to the Change of Control Offer have been complied with.

 

The Company shall not be required to make a Change of Control Offer with respect to the Notes if a third party makes such an offer in the manner, at the times and otherwise in compliance with the requirements for such an offer made by the Company and such third party purchases all the Notes properly tendered and not withdrawn under its offer.

 

The Company shall comply in all material respects with the requirements of Rule 14e-1 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and any other securities laws and regulations thereunder to the extent those laws and regulations are applicable in connection with the repurchase of the Notes as a result of a Change of Control

 

6

 

Triggering Event. To the extent that the provisions of any such securities laws or regulations conflict with the Change of Control Offer provisions of the Notes, the Company shall comply with those securities laws and regulations and shall not be deemed to have breached the Company’s obligations under the Change of Control Offer provisions of the Notes by virtue of any such conflict.

 

For purposes of the foregoing provisions relating to a Change of Control Offer, the following definitions are applicable:

 

“Change of Control” means the occurrence of any of the following after the date of issuance of the Notes:

 

1.                                      the direct or indirect sale, lease, transfer, conveyance or other disposition (other than by way of merger or consolidation), in one or a series of related transactions, of all or substantially all of the assets of the Company and its subsidiaries taken as a whole to any “person” or “group” (as those terms are used in Section 13(d)(3) of the Exchange Act) other than to the Company and/or one or more of its subsidiaries;

 

2.                                      the consummation of any transaction (including, without limitation, any merger or consolidation) the result of which is that any “person” or “group” (as those terms are used in Section 13(d)(3) of the Exchange Act, it being agreed that an employee of the Company or any of its subsidiaries for whom shares are held under an employee stock ownership, employee retirement, employee savings or similar plan and whose shares are voted in accordance with the instructions of such employee shall not be a member of a “group” (as that term is used in Section 13(d)(3) of the Exchange Act) solely because such employee’s shares are held by a trustee under said plan) becomes the “beneficial owner” (as defined in Rules 13d-3 and 13d-5 under the Exchange Act), directly or indirectly, of the Company’s Voting Stock representing more than 50% of the voting power of its outstanding Voting Stock;

 

3.                                      the Company consolidates with, or merges with or into, any Person, or any Person consolidates with, or merges with or into, the Company, in any such event pursuant to a transaction in which any of the Company’s outstanding Voting Stock or Voting Stock of such other Person is converted into or exchanged for cash, securities or other property, other than any such transaction where the Company’s Voting Stock outstanding immediately prior to such transaction constitutes, or is converted into or exchanged for, Voting Stock representing more than 50% of the voting power of the Voting Stock of the surviving Person immediately after giving effect to such transaction;

 

4.                                      during any period of 24 consecutive calendar months, the majority of the members of the Company’s Board of Directors shall no longer be composed of individuals (a) who were members of the Company’s Board of Directors on the first day of such period or (b) whose election or nomination to the Company’s Board of Directors was approved by individuals referred to in clause (a) above constituting, at the time of such election or nomination, at least a majority of the Company’s Board of Directors or, if directors are nominated by a committee of the Company’s Board of Directors, constituting at the time of such nomination, at least a majority of such committee; or

 

7

 

5.                                      the adoption of a plan relating to the Company’s liquidation or dissolution.

 

“Change of Control Triggering Event” means, with respect to the Notes, the Notes cease to be rated Investment Grade by each of the Rating Agencies on any date during the period (the “Trigger Period”) commencing 60 days prior to the first public announcement by the Company of any Change of Control (or pending Change of Control) and ending 60 days following consummation of such Change of Control (which Trigger Period will be extended following consummation of a Change of Control for so long as any of the Rating Agencies has publicly announced that it is considering a possible ratings change). If a Rating Agency is not providing a rating for the Notes at the commencement of any Trigger Period, the Notes will be deemed to have ceased to be rated Investment Grade by such Rating Agency during that Trigger Period.  Notwithstanding the foregoing, no Change of Control Triggering Event will be deemed to have occurred in connection with any particular Change of Control unless and until such Change of Control has actually been consummated.

 

“Investment Grade” means a rating of Baa3 or better by Moody’s (or its equivalent under any successor rating category of Moody’s) and a rating of BBB- or better by S&P (or its equivalent under any successor rating category of S&P), and the equivalent investment grade credit rating from any replacement rating agency or rating agencies selected by the Company under the circumstances permitting the Company to select a replacement agency and in the manner for selecting a replacement agency, in each case as set forth in the definition of “Rating Agency.”

 

“Moody’s” means Moody’s Investors Service, Inc., a subsidiary of Moody’s Corporation, and its successors.

 

“Rating Agency” means each of Moody’s and S&P; provided, that if any of Moody’s or S&P ceases to provide rating services to issuers or investors, the Company may appoint another “nationally recognized statistical rating organization” within the meaning of Section 3(a)(62) of the Exchange Act as a replacement for such Rating Agency; provided, that the Company shall give notice of such appointment to the Trustee.

 

“S&P” means S&P Global Ratings, a division of S&P Global Inc., and its successors.

 

“Voting Stock” of any specified Person as of any date means the capital stock of such Person that is at the time entitled to vote generally in the election of the board of directors of such Person.

 

If an Event of Default with respect to Notes of this series shall occur and be continuing, the principal of the Notes of this series may (subject to the conditions set forth in the Indenture) be declared due and payable in the manner and with the effect provided in the Indenture.

 

The Indenture contains provisions for defeasance at any time of the Company’s obligations in respect of (i) the entire indebtedness of this Note or (ii) certain covenants with respect to this Note, in each case upon compliance with certain conditions set forth therein.

 

8

 

The Indenture permits, with certain exceptions as therein provided, the amendment thereof and the modification of the rights and obligations of the Company and the rights of the Holders of the Notes of each series to be affected under the Indenture at any time by the Company and the Trustee with the consent of the Holders of not less than a majority in aggregate principal amount of the Notes at the time Outstanding of each series to be affected and, for certain purposes, without the consent of the Holders of any Notes at the time Outstanding. The Indenture also contains provisions permitting the Holders of specified percentages in aggregate principal amount of the Notes of each series at the time Outstanding, on behalf of the Holders of all Notes of such series, to waive compliance by the Company with certain provisions of the Indenture and certain past defaults under the Indenture and their consequences. Any such consent or waiver by the Holder of this Note shall be conclusive and binding upon such Holder and upon all future Holders of this Note and of any Note issued upon the registration of transfer hereof or in exchange hereof or in lieu hereof, whether or not notation of such consent or waiver is made upon this Note.

 

No reference herein to the Indenture and no provision of this Note or of the Indenture shall alter or impair the obligation of the Company, which is absolute and unconditional, to pay the principal of (and premium, if any) and interest on this Note at the times, place and rate, and in the coin or currency, herein prescribed.

 

As provided in the Indenture and subject to certain limitations therein set forth, the transfer of this Note is registrable in the Security Register, upon surrender of this Note for registration of transfer at the office or agency of the Company in any place where the principal of (and premium, if any) and interest on this Note are payable, duly endorsed by, or accompanied by a written instrument of transfer in form satisfactory to the Company and the Security Registrar duly executed by, the Holder hereof or such Holder’s attorney duly authorized in writing, and thereupon one or more new Notes of this series and of like tenor of authorized denominations and for the same aggregate principal amount, will be issued to the designated transferee or transferees.

 

The Notes of this series are issuable only in registered form without coupons in denominations of $2,000 and integral multiples of $1,000 above that amount.  As provided in the Indenture and subject to certain limitations therein set forth, the Notes of this series are exchangeable for a like aggregate principal amount of Notes of this series and of like tenor of a different authorized denomination, as requested by the Holder surrendering the same.

 

No service charge shall be made for any such registration of transfer or exchange, but the Company may require payment of a sum sufficient to cover any tax or other governmental charge payable in connection therewith.

 

The Company will not be obligated to redeem or purchase the Notes pursuant to any sinking fund or analogous provision. Section 403 of the Indenture relating to satisfaction, discharge and defeasance shall apply to the Notes.

 

Prior to due presentment of this Note for registration of transfer, the Company, the Trustee and any agent of the Company or the Trustee may treat the Person in whose name this Note is registered in the Security Register as the owner hereof for all purposes, whether or

 

9

 

not this Note be overdue, and neither the Company, the Trustee nor any such agent shall be affected by notice to the contrary.

 

The Notes shall be governed by and construed in accordance with the laws of the State of New York.

 

All terms used in this Note which are defined in the Indenture shall have the meanings assigned to them in the Indenture.

 

10

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00262-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00262-of-00352.parquet"}]]